Displaying 241 - 243 of 243
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: β-human chorionic gonadotropin
User: Female
Hormonal: No
Duration Type: Short-acting
Developer: Talwar Research Foundation, Indian Council for Medical Research
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 21 - 30 of 70
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: National Research Institute for Family Planning in Beijing
Development Stage: Prototype Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Alternative Name: Inhibition of Vas Propulsive Contractility
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: King's College, London
Development Stage: Lead Optimization
Alternative Name: K4K20S4
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other, Other
Development Stage: Lead Optimization
Alternative Name: Plasma Membrane Calcium ATPase (PMCA) Inhibitors
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: University of Manchester, Max Planck Institute
Alternative Name: Electrospun fiber meshes
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Development Stage: Prototype Development
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Contraline, LLC
Development Stage: Lead Optimization
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Alternative Name: Epididymal Peptidase Inhibitor
Target
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Evestra, Inc.
Development Stage: Prototype Development

Pages

Displaying 61 - 70 of 121
User: Female
Hormonal: No
Duration Type: Emergency
Delivery Method: Oral
Developer: CONRAD
Development Stage: Phase II
User: Female
Hormonal: No
Delivery Method: Vaginal Ring
Developer: Andromaco
Development Stage: Phase I
Alternative Name: MENT Transdermal Gel
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council
Development Stage: Phase I
Alternative Name: MENT Acetate Implant, 7α-methyl-19-nortestosterone
User: Male
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: Regulatory
Alternative Name: MAP, Microneedle Patch
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Other
Developer: PATH, Queen's University Belfast, ViiV Healthcare, Population Council, LTS Lohmann Therapie-Systeme AG
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: FHI 360, University of Washington
Development Stage: Pre-clinical
Alternative Name: MZCL Combination IVR
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, ProMed Pharma
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Delivery Method: Subdermal
Developer: Shandong University
Development Stage: Pre-clinical
Alternative Name: Nestorone (NES) + Estradiol (E2) Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: NICHD, Population Council
Development Stage: Phase II

Pages

Displaying 1 - 10 of 52
Alternative Name: Smaller/Nulliparous Copper IUD, Liberté TT380 Short, Micro T
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: SRA/WHO PQ Approved
Alternative Name: Nestorone + Ethinyl Estradiol One-Year Contraceptive Vaginal Ring, NES + EE Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Population Council, NICHD, WHO, USAID, NIH, Bill & Melinda Gates Foundation, Avis and Clifford Barrus Medical Foundation
Development Stage: SRA/WHO PQ Approved
Alternative Name: SILCS Diaphragm
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Barrier
Developer: PATH, CONRAD, SILCS, Inc., Kessel Marketing & Vertriebs GmbH
Development Stage: SRA/WHO PQ Approved
Alternative Name: Saheli; Ormeloxifene
User: Female
Hormonal: No
Duration Type: Short-acting, Emergency
Delivery Method: Oral
Developer: Central Drug Research Institute, India, HLL Lifecare Limited
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Chongqing Medical Equipment Factory Co., Ltd.
Development Stage: Marketed
Alternative Name: Nanocomposite Copper (Cu) IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tongji Medical College at Huazhong University of Science and Technology
Development Stage: Marketed
Alternative Name: l'Amour®; Jeitosa®
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Concept Foundation, Sun Pharmaceuticals, India, WHO HRP, PT. Tunggal Idaman Abdi
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: DKT International, PT Harsen
Development Stage: Marketed

Pages

CSV